01891nas a2200385   4500000000100000008004100001653002400042653002800066653001600094653003200110653001400142653002400156653000900180653001100189653001100200653003000211653001700241653000800258653003100266653004800297653002100345653002300366653001500389653001200404100001200416700001300428700001200441700001100453700001300464245008500477300001000562490000700572520091200579022001401491       2015                            d10aVaccines, Synthetic10aVaccines, Contraceptive10aVaccination10aRecombinant Fusion Proteins10aPregnancy10aMice, Inbred BALB C10aMice10aHumans10aFemale10aEscherichia coli Proteins10aEnterotoxins10aDNA10aContraception, Immunologic10aChorionic Gonadotropin, beta Subunit, Human10aBacterial Toxins10aAntibody Formation10aAntibodies10aAnimals1 aNand KN1 aGupta JC1 aPanda A1 aJain S1 aTalwar G00aPriming with DNA Enhances Considerably the Immunogenicity of hCG β-LTB Vaccine.  a302-80 v743 a<p><strong>PROBLEM: </strong>Necessity to elicit antibody response above the protective threshold titres by sexually active women immunized to prevent pregnancy.</p>

<p><strong>METHOD OF STUDY: </strong>Recombinant hCGβ-LTB vaccine expressed as both DNA and protein. Balb C mice employed for testing immunogenicity.</p>

<p><strong>RESULTS: </strong>Necessity to give three primary injections of the vaccine to elicit proper antibody response. Immunization twice with DNA form of the vaccine at fortnightly interval followed by the protein elicits a distinctly higher antibody response than proteinic vaccine alone. Antibodies generated are bio-effective against hCG.</p>

<p><strong>CONCLUSION: </strong>Immunization with the DNA form of the recombinant hCGβ-LTB vaccine twice at fortnightly interval followed by the proteinic form of the vaccine induces distinctly higher antibody response.</p>
  a1600-0897